Background. Patients coinfected with syphilis and human immunodeficiency virus (HIV) may have a slower decrease in rapid plasma reagin (RPR) titers. Currently a single dose of 2.4 million units of intramuscular benzathine penicillin G (BPG) is recommended for the treatment of early syphilis. Some observational studies have suggested that this regimen may lead to high failure rates in coinfected patients.
Syphilis remains a significant health problem worldwide, with an estimated 10.6 million new cases per year [1] . In the United States, the rate of primary and secondary syphilis increased each year from 2001 through 2009 after a nadir in 2000. In 2010, the overall rate decreased for the first time in 10 years. While the rate remained unchanged in 2011, the rate increased 22% during 2011-2013 [2] . Due to shared transmission route and risk factors, coinfection with syphilis and human immunodeficiency virus (HIV) is not uncommon [3] . In the United States, the coinfection rate is particularly high among men who have sex with men, with the reported rate ranging from 15.8% in Los Angeles to 47.4% in Philadelphia in 2013 [2] .
Few studies have evaluated the response to treatment of syphilis in HIV-infected patients [4, 5] . These studies were done prior to the highly active antiretroviral therapy (HAART) era. They suggest that patients with HIV have a slower decrease in RPR titer after treatment and that they may progress to neurosyphilis in earlier stages. This led to speculation regarding the need to treat early syphilis with an increased total dose of penicillin [6] .
The Centers for Disease Control and Prevention's (CDC) sexually transmitted disease treatment guidelines advocate treating HIV-infected patients who have primary or secondary syphilis with the same number of doses of penicillin as for HIV-uninfected patients [7] . This recommendation has remained unchanged in the last several guideline cycles. The evidence for it is mainly based on the result of 1 prospective randomized trial, which did not find a significant difference in the clinical response between patients treated with 2.4 million units of benzathine penicillin G (BPG) and those treated with an additional 10-day course of amoxicillin and probenecid [8] .
However, of 541 patients enrolled in that study, only 18.7% had HIV infection. In addition, the rate of follow-up was low (52%) at 12 months.
To our knowledge, there have been no randomized controlled trials comparing the efficacy of a single dose of BPG with that of 3 doses of BPG administered at 1-week intervals for early syphilis in HIV-infected patients. The results of observational studies have been conflicting. In a single-center study, we reported higher rates of treatment failure among HIV-infected patients treated with 2.4 million units (28%) compared to those treated with 7.2 million units (5%) of BPG [9] . Given the limited evidence to guide syphilis management in HIV-infected patients, as many as 62% of infectious diseases specialists choose to administer 3 doses of BPG for secondary syphilis despite the CDC recommendation [10, 11] .
We carried out a randomized controlled trial to compare the efficacy of 3-dose vs single-dose regimens of intramuscular BPG for the treatment of early syphilis in HIV-infected patients.
METHODS

Study Design
We conducted a prospective, randomized, open-label study at 3 clinical sites including Thomas Street Health Center and North West Clinic (Harris Health System), and the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) in Houston, Texas. The study was approved by the Institutional Review Board of Baylor College of Medicine, the Harris Health System Office of Research, and the Research and Development Committee at the MEDVAMC.
Participants
Patients were eligible for inclusion in the study if they were aged ≥18 years, had HIV infection diagnosed by enzymelinked immunosorbent assay and Western blot testing, and had untreated early syphilis (defined as primary, secondary, or early latent syphilis). The diagnosis of syphilis was made on the basis of a positive rapid plasma reagin (RPR) and Treponema pallidum particle agglutination (TP-PA) tests. RPR and TP-PA tests were performed in the central laboratories of Harris Health System (for patients enrolled at Thomas Street Health Center and North West Clinic) and MEDVAMC (for patients enrolled there). Patients with compatible genital, anal, or oropharyngeal ulcers were classified as having primary syphilis. Full physical examination was performed by a licensed clinician (physician or physician assistant) with special attention to signs of primary and secondary syphilis, including evaluation of regional lymph nodes. Patients were classified to have secondary syphilis if they had cutaneous rash or mucosal lesions. Patients with a positive serological test without other evidence of disease were classified to have early latent syphilis if they had a documented test result within 12 months and seroconversion or ≥4-fold increase in titer. Exclusion criteria were history of penicillin allergy, diagnosis of late latent syphilis, and antibiotic use with significant activity against Treponema pallidum (including macrolides, tetracyclines, and cephalosporins) within the preceding 2 weeks.
Treatment and Follow-up
After obtaining written informed consent, we randomly assigned patients to either a single intramuscular injection of 2.4 million units of BPG (standard therapy) or 3 doses (enhanced therapy) of intramuscular BPG administered weekly (a total of 7.2 million units). Simple randomization was performed using a random number table. All injections were given by a trained nurse at study sites. Performance of lumbar punctures was not a study procedure but could be ordered at the discretion of the treating physician.
Patients were interviewed about symptoms, interval sexual activity, and interval antibiotic exposure at the initial visit and at each follow-up visit at 3, 6, 9, and 12 months. Serum samples were also obtained at initial visit and each follow-up visit for serological testing for syphilis. Other pertinent laboratory results were collected at each visit. Treatment success was defined as a decrease in RPR titer of ≥2 dilutions (4-fold) from the initial RPR titer during the 12-month follow-up period. Treatment effects were also analyzed in prespecified subgroups including CD4 T-cell count at baseline (≤350 and >350 cells/ µL), RPR titer at baseline (<32 and ≤32), virologic suppression (defined as HIV RNA load ≤50 copies/mL), and syphilis stage (primary, secondary, or early latent).
Statistical Analysis
Both intention-to-treat and per-protocol analyses were performed. The intention-to-treat analysis included all participants who underwent randomization. For patients with missing data, we assumed that these patients have failed treatment. For the per-protocol analysis, we excluded patients who were lost to follow-up (5 patients) and those who received extra doses of BPG in the standard therapy group (1 patient).
Sample size calculations were based on a 2-tailed, 2-sample comparison of proportions with a type 1 error of 0.05. We hypothesized a treatment success rate of 95% (or 5% failure rate) in the enhanced therapy group and 75% (or 25% failure rate) in the standard treatment group. The power was set at 80%. With these parameters, the required sample size in each group was 59 subjects (total 118 subjects).
We used conventional measurements of central location and dispersion to describe the data. Characteristics of patients in both study groups were compared using a Student t test for continuous variables, and χ 2 test or Fisher exact test for categorical variables. The 95% confidence interval (CI) is reported for the main outcome. A P value < .05 was considered statistically significant.
RESULTS
Study Population
From June 2009 through April 2013, 108 patients were screened; of those, 64 patients were included in the study (Figure 1 ). Among included patients, 35 were randomized to standard therapy with a single dose of BPG and 29 to enhanced therapy with 3 doses of BPG. The baseline characteristics of subjects in both groups are shown in Table 1 . The mean age of study participants was 35 years. The participants were predominantly male (95%) and men who have sex with men (84%). Across both groups, 37 (58%) were African American, 20 (31%) were Hispanic, and 7 (11%) were white. Four patients (6%) had primary syphilis, 39 (61%) patients had secondary syphilis, and 21 (33%) patients had early latent syphilis. Thirty-eight (59%) of subjects had a previous diagnosis of syphilis. The mean CD4 count was 388 cells/µL and 64% of patients were on HAART at the time of syphilis diagnosis. Nineteen of 41 (49%) subjects on antiretroviral therapy had undetectable HIV RNA. The median RPR titer was 1:128 (interquartile range, 1:32-1:256). There were no statistically significant differences in any of the baseline characteristics between the standard therapy group and the enhanced therapy group.
Response to Therapy
In the intention-to-treat analysis (Figure 2 ), treatment success rates by 12 months of follow-up were 80% (28 of 35 subjects) in the standard therapy group and 93% (27 of 29 subjects) in the enhanced therapy group (absolute difference, 13% [95% CI, -5% to 30%]; P = .17). There was a significant decrease in RPR geometric mean titers by the end of follow-up (12 months) in both treatment groups ( Figure 3) . Two of 5 patients who had been lost to follow-up in the standard therapy group returned to the clinic at 18 and 24 months, respectively, and were noted to have ≥4-fold decreases in RPR titers.
In a post hoc analysis, after removing those patients with early latent syphilis who did not have a negative RPR titer in the preceding year to enrollment, treatment success rates were 80% (24 of 30) and 90% (19 of 21) in the standard and enhanced treatment groups, respectively (P = .45).
In the per-protocol analysis (Figure 2 ), treatment success rates were 93% (27 of 29) and 100% (27 of 27) in the standard and enhanced groups, respectively (absolute difference, 7% [95% CI, -7% to 22%]; P = .49). The 2 patients who did not respond to a single dose of BPG had RPR titers of 4 and 32, respectively, at baseline and 2 and 16, respectively, at the 12-month follow-up.
Among subjects who had at least 1 follow-up RPR titer, 9 patients experienced seroconversion (negative RPR). Of those, 4 were in the standard group and 5 in the enhanced group (P = .72).
No significant changes were seen when treatment effect was evaluated in subgroup analyses (Table 2) by CD4 count at baseline (≤350 and >350 cells/µL), HIV RNA load, use of antiretroviral therapy at enrollment, RPR titer at enrollment (<32 and ≥32), or syphilis stage (primary, secondary, or early latent). Of those patients with undetectable HIV RNA viral load, only 1 of 20 (5%) did not achieve treatment success. This patient received a single dose of intramuscular benzathine penicillin. In contrast, 8 of 44 (18%) patients with detectable HIV viremia did not achieve treatment success (P = .25). Six of them had received single-dose benzathine penicillin and the remaining 2 received the 3-dose regimen. 
Adverse Events
We did not observe any Jarisch-Herxheimer reactions after administration of BPG. None of the participants in our study developed neurologic symptoms during the 12-month follow-up period.
We recorded no deaths among study participants.
DISCUSSION
This is, to our knowledge, the first randomized clinical trial comparing the treatment response between single-dose (standard) and 3-dose (enhanced) regimens of intramuscular benzathine penicillin for early syphilis in HIV-infected patients.
We found no significant difference in treatment success rates, defined as a 4-fold decrease in RPR titers at 12 months, between standard and enhanced regimens of intramuscular benzathine penicillin G. The overall serologic response in our study was 86% by intention-to-treat and 96% by per-protocol analyses, similar to previously reported response rates [12] [13] [14] . In addition, we did not observe any significant changes after evaluating treatment effects by CD4 count at baseline (≤350 and >350 cells/µL), use of antiretroviral therapy at enrollment, HIV virologic suppression, RPR titer at enrollment (<32 and ≥32), and syphilis stage (primary, secondary, or early latent).
Two patients in the single-dose BPG group did not experience a ≥4-fold decrease in RPR titers at 12 months; however, they eventually experienced a 4-fold decrease in RPR titers after our follow-up ended. A previous study showed that approximately 6% of HIV-infected patients with early syphilis have a ≥4-fold decline in baseline RPR titers between 12 months and 24 months after treatment [12] .
A prospective observational study in HIV-infected patients with early syphilis indicated that single-dose BPG was associated with a higher serological failure rate and shorter time to treatment failure compared with 3 weekly doses of BPG [15] . In that study, those subjects who had initially experienced adequate serological response after treatment but then developed a ≥4-fold increase in RPR titers were considered to have treatment failure. These patients may have been reinfected after appropriate treatment response. When these patients were excluded, there was no difference in the proportions of patients who had serologic response between the 2 groups (88.1% in the 1-dose group and 86% in the 3-dose group). Other studies have also indicated that the 2 regimens (1 vs 3 doses of BPG) are similar in efficacy [12, 13, 16] .
Our results support the hypothesis that HIV infection does not affect the serologic response to BPG treatment in patients with early syphilis. Evaluation of alternative therapies to BPG that have been studied in non-HIV-infected individuals, such as azithromycin [17] , may also be warranted.
Our study has some limitations. First, due to slow enrollment leading to a sample size lower than that planned, our study may have been underpowered to detect a small but clinically significant difference in the treatment outcomes between treatment regimens, particularly among those subjects with early latent syphilis and detectable HIV RNA loads. Second, 64% of our study participants were on antiretroviral therapy at the time of syphilis diagnosis with a mean CD4 count of 388 cells/µL. Although this proportion is within the expected range of antiretroviral use, our results may not be applicable to a more immunocompromised population or a population not on antiretroviral therapy. However, all 11 patients in the standard therapy group and 5 of 6 patients in the enhanced therapy group whose CD4 count was <200 cells/µL at the time of syphilis diagnosis had an appropriate serologic response. Third, we used the ≥4-fold decline in nontreponemal antibody titer as outcome measure. Although serologic response is the most commonly used surrogate measure to evaluate the efficacy of syphilis treatment, the clinical implications of such serologic response remain unclear [18] . Oboho et al [19] reported that nontreponemal antibody titers in HIV-infected patients might be influenced by factors other than syphilis disease activity, such as the use of antiretrovirals and intravenous drugs. Furthermore, some authors including Tuddenham and Ghanem [20] advocate the use of clinically oriented primary outcomes such as progression to neurosyphilis when evaluating the efficacy of syphilis therapy. Our study was not designed to compare differences in the occurrence of neurosyphilis between groups. Although we did not perform lumbar punctures as part of our study, none of the patients developed symptoms suggestive of neurosyphilis during the 12-month follow-up.
In conclusion, our findings suggest that a 3-dose regimen of BPG does not improve outcome in HIV-infected patients with early syphilis compared with a single-dose regimen. Larger, ideally multicenter, studies are needed to confirm our findings. In the meantime, our results support the current CDC recommendations to use a single dose of BPG for treatment of early syphilis in HIV-infected patients.
